FDAnews Drug Daily Bulletin

Former FDA Head Slams J&J Over Risperdal (Pharmalot blog)
Johnson & Johnson’s (J&J) latest setback in its seemingly futile attempts to defend its Risperdal marketing is trying to keep former FDA Commissioner David Kessler from testifying in a case involving a teenage boy who claims the drug caused him to grow breasts, blogger Ed Silverman writes. A scathing report Kessler wrote about J&J’s conduct might also have something to do with it, Silverman adds. “In his report, Kessler reviewed various efforts to promote Risperdal to physicians allegedly without providing sufficient side effect data.”